SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Pharmaceuticals informs about media release

24 Mar 2021 Evaluate

Glenmark Pharmaceuticals has informed that it has attached a media release on 24th March 2021 titled ‘Glenmark Pharmaceuticals receives ANDA approval for Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg: Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGT exclusivity’ which is self-explanatory.

The above information is a part of company’s filings submitted to BSE.

Glenmark Pharma. Share Price

2283.85 18.60 (0.82%)
10-Jul-2026 11:45 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1939.30
Dr. Reddys Labs. 1240.50
Cipla 1449.95
Zydus Lifesciences 1152.15
Lupin 2501.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: